In a 2-year trial with semaglutide 0.5 mg and 1 mg once-weekly injection in adult patients with type 2 diabetes and high cardiovascular risk, diabetic retinopathy complications (which was a 4-component adjudicated endpoint) occurred in patients treated with semaglutide injection (3.0%) compared to placebo (1.8%)
Semaglutide for weight loss (Wegovy) is approved for use in Canada, but is not being sold here, which has likely contributed to the Ozempic shortage
(PubMed) Burk RF, Norsworthy BK, Hill KE, Motley AK, Byrne DW
Therapeutic potential of short-chain fatty acids in gastrointestinal diseases
Human blood-brain barrier insulin receptor
doi: 10.1016/j.crohns.2012.07.010 238 RastegarpanahMMalekzadehRVahediHMohammadiMElahiEChaharmahaliMet al